Jonathan Wolleben
Stock Analyst at Citizens
(4.63)
# 189
Out of 5,117 analysts
235
Total ratings
54.74%
Success rate
30.67%
Average return
Main Sectors:
Stocks Rated by Jonathan Wolleben
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MIRM Mirum Pharmaceuticals | Maintains: Market Outperform | $95 → $140 | $75.56 | +85.28% | 13 | Dec 19, 2025 | |
| DBVT DBV Technologies | Maintains: Market Outperform | $21 → $45 | $16.99 | +164.86% | 16 | Dec 17, 2025 | |
| RYTM Rhythm Pharmaceuticals | Maintains: Market Outperform | $141 → $167 | $101.86 | +63.95% | 6 | Dec 12, 2025 | |
| GPCR Structure Therapeutics | Maintains: Market Outperform | $87 → $120 | $62.77 | +91.17% | 11 | Dec 12, 2025 | |
| SGMT Sagimet Biosciences | Maintains: Market Outperform | $33 → $35 | $5.54 | +531.77% | 9 | Nov 14, 2025 | |
| SVRA Savara | Maintains: Market Outperform | $11 → $10 | $5.80 | +72.41% | 10 | Nov 13, 2025 | |
| SPRB Spruce Biosciences | Maintains: Market Outperform | $254 → $259 | $82.12 | +215.39% | 9 | Nov 11, 2025 | |
| KALV KalVista Pharmaceuticals | Maintains: Market Outperform | $29 → $28 | $15.66 | +78.80% | 6 | Nov 11, 2025 | |
| PTGX Protagonist Therapeutics | Maintains: Market Outperform | $69 → $102 | $84.18 | +21.17% | 13 | Nov 7, 2025 | |
| CRNX Crinetics Pharmaceuticals | Maintains: Market Outperform | $143 → $108 | $48.18 | +124.16% | 17 | Nov 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $15 → $14 | $4.09 | +242.30% | 14 | Nov 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $27 → $25 | $7.41 | +237.38% | 10 | Nov 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $485 → $527 | $588.00 | -10.37% | 14 | Nov 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Outperform | $20 | $8.16 | +145.10% | 1 | Nov 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $12.82 | - | 4 | Oct 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $20 → $29 | $11.55 | +151.08% | 18 | Oct 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $18 | $3.36 | +435.71% | 13 | Aug 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $55 → $52 | $24.88 | +109.00% | 12 | Aug 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $9 → $8 | $2.86 | +179.72% | 2 | Aug 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $8 | $2.07 | +287.41% | 8 | Jun 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $15 | $0.86 | +1,648.46% | 3 | Jun 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $19 | $5.18 | +266.80% | 9 | May 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Outperform | $38 | $29.31 | +29.65% | 1 | Apr 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $55 → $50 | $45.16 | +10.72% | 1 | Dec 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $90 | $66.42 | +35.50% | 1 | Dec 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Perform | n/a | $135.87 | - | 1 | Dec 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Accumulate | $420 → $485 | $593.39 | -18.27% | 1 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $8 | $0.68 | +1,082.73% | 11 | Apr 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $25 → $24 | $30.74 | -21.93% | 1 | May 12, 2023 |
Mirum Pharmaceuticals
Dec 19, 2025
Maintains: Market Outperform
Price Target: $95 → $140
Current: $75.56
Upside: +85.28%
DBV Technologies
Dec 17, 2025
Maintains: Market Outperform
Price Target: $21 → $45
Current: $16.99
Upside: +164.86%
Rhythm Pharmaceuticals
Dec 12, 2025
Maintains: Market Outperform
Price Target: $141 → $167
Current: $101.86
Upside: +63.95%
Structure Therapeutics
Dec 12, 2025
Maintains: Market Outperform
Price Target: $87 → $120
Current: $62.77
Upside: +91.17%
Sagimet Biosciences
Nov 14, 2025
Maintains: Market Outperform
Price Target: $33 → $35
Current: $5.54
Upside: +531.77%
Savara
Nov 13, 2025
Maintains: Market Outperform
Price Target: $11 → $10
Current: $5.80
Upside: +72.41%
Spruce Biosciences
Nov 11, 2025
Maintains: Market Outperform
Price Target: $254 → $259
Current: $82.12
Upside: +215.39%
KalVista Pharmaceuticals
Nov 11, 2025
Maintains: Market Outperform
Price Target: $29 → $28
Current: $15.66
Upside: +78.80%
Protagonist Therapeutics
Nov 7, 2025
Maintains: Market Outperform
Price Target: $69 → $102
Current: $84.18
Upside: +21.17%
Crinetics Pharmaceuticals
Nov 7, 2025
Maintains: Market Outperform
Price Target: $143 → $108
Current: $48.18
Upside: +124.16%
Nov 7, 2025
Maintains: Market Outperform
Price Target: $15 → $14
Current: $4.09
Upside: +242.30%
Nov 5, 2025
Maintains: Market Outperform
Price Target: $27 → $25
Current: $7.41
Upside: +237.38%
Nov 5, 2025
Maintains: Market Outperform
Price Target: $485 → $527
Current: $588.00
Upside: -10.37%
Nov 3, 2025
Initiates: Market Outperform
Price Target: $20
Current: $8.16
Upside: +145.10%
Oct 15, 2025
Downgrades: Market Perform
Price Target: n/a
Current: $12.82
Upside: -
Oct 1, 2025
Maintains: Market Outperform
Price Target: $20 → $29
Current: $11.55
Upside: +151.08%
Aug 19, 2025
Reiterates: Market Outperform
Price Target: $18
Current: $3.36
Upside: +435.71%
Aug 13, 2025
Maintains: Market Outperform
Price Target: $55 → $52
Current: $24.88
Upside: +109.00%
Aug 12, 2025
Maintains: Market Outperform
Price Target: $9 → $8
Current: $2.86
Upside: +179.72%
Jun 27, 2025
Reiterates: Market Outperform
Price Target: $8
Current: $2.07
Upside: +287.41%
Jun 24, 2025
Reiterates: Market Outperform
Price Target: $15
Current: $0.86
Upside: +1,648.46%
May 23, 2025
Reiterates: Market Outperform
Price Target: $19
Current: $5.18
Upside: +266.80%
Apr 10, 2025
Initiates: Market Outperform
Price Target: $38
Current: $29.31
Upside: +29.65%
Dec 18, 2024
Maintains: Market Outperform
Price Target: $55 → $50
Current: $45.16
Upside: +10.72%
Dec 16, 2024
Reiterates: Market Outperform
Price Target: $90
Current: $66.42
Upside: +35.50%
Dec 16, 2024
Reiterates: Market Perform
Price Target: n/a
Current: $135.87
Upside: -
Nov 13, 2024
Downgrades: Accumulate
Price Target: $420 → $485
Current: $593.39
Upside: -18.27%
Apr 19, 2024
Reiterates: Market Outperform
Price Target: $8
Current: $0.68
Upside: +1,082.73%
May 12, 2023
Maintains: Outperform
Price Target: $25 → $24
Current: $30.74
Upside: -21.93%